Research programme: bispecific antibody therapeutics - Merus/Ono Pharmaceutical

Drug Profile

Research programme: bispecific antibody therapeutics - Merus/Ono Pharmaceutical

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator Merus; Ono Pharmaceutical
  • Class Bispecific antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 19 Oct 2016 Merus signs additional agreement with Ono Pharmaceutical for CMC activities and receives milestone payment for bispecific antibody therapeutic development in Autoimmune disorders
  • 08 Apr 2015 Merus receives milestone payment from Ono Pharmaceutical for bispecific antibody therapeutic development in Autoimmune disorders ,
  • 08 Apr 2014 Preclinical trials in Autoimmune disorders in Japan before April 2015 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top